An AllTrials project

NCT03587116: An ongoing trial by Pfizer

This trial is ongoing. It must report results 2 years, 6 months from now.

Full data

Full entry on ClinicalTrials.gov NCT03587116
Title AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, MULTI-CENTER, LEAD-IN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSPECTIVE EFFICACY AND SELECTED SAFETY DATA OF FACTOR IX (FIX) PROPHYLAXIS REPLACEMENT THERAPY IN THE USUAL CARE SETTING OF MODERATELY SEVERE TO SEVERE ADULT HEMOPHILIA B SUBJECTS (FIX:C≤2%) WHO ARE NEGATIVE FOR NEUTRALIZING ANTIBODIES (NAB) TO ADENO-ASSOCIATED VIRUS VECTOR (AAV)-SPARK100
Results Status Ongoing
ACT or pACT? This is what FDAAA officially calls an "Applicable Clinical Trial"
Start date July 26, 2018
Completion date Dec. 6, 2020
Required reporting date Dec. 6, 2021, midnight
Actual reporting date None
Date last checked at ClinicalTrials.gov May 16, 2019
Days late None